益气疏风温阳化饮方治疗变应性鼻炎-哮喘综合征临床研究

目的:观察益气疏风温阳化饮方治疗肺脾两虚、痰饮内停型变应性鼻炎-哮喘综合征(CARAS)的临床疗效。方法:将60例患者按照就诊顺序分为治疗组和对照组各30例,治疗组予益气疏风温阳化饮方口服治疗,对照组予布地奈德福莫特罗吸入和孟鲁司特钠片口服治疗。两组均以1个月为1个疗程,共治疗2个疗程。比较两组治疗前后变应性鼻炎症状积分、支气管哮喘症状积分、血清嗜酸性粒细胞计数、肺功能指标水平,评价疗效。结果:治疗后,两组变应性鼻炎症状积分、哮喘症状积分均低于治疗前,差异有统计学意义(P<0.05),且治疗组积分低于对照组,差异有统计学意义(P<0.05)。治疗组血清嗜酸性粒细胞计数少于治疗前,差异有统计学意义(P<0.05),且治疗组血清嗜酸性粒细胞计数少于对照组,差异有统计学意义(P<0.05)。治疗组用力肺活量(FVC)、第一秒用力呼气量(FEV1)、FEV1/FVC、呼气流量峰值(PEF)、PEF25%、PEF50%、PEF75%和用力呼气中期流量(FEF25%~75%)均高于治疗前,差异有统计学意义(P<0.05),对照组仅PEF高于治疗前,差异有统计学意义(P<0.05)。治疗组和对照组总有效率分别为96.7%、80.0%,治疗组总有效率高于对照组,差异有统计学意义(P<0.05)。结论:益气疏风温阳化饮方治疗肺脾两虚、痰饮内停型CARAS,能改善患者临床症状和肺功能,提高疗效。

Clinical Study on Yiqi Shufeng Wenyang Huayin Formula(益气疏风温阳化饮方) in Treatment of Combined Allergic Rhinitis and Asthma Syndrome

Objective:To observe the clinical curative efficacy of Yiqi Shufeng Wenyang Huayin Formula(益气疏风温阳化饮方,YQSFWYHYF) on treating combined allergic rhinitis and asthma syndrome(CARAS)of the lung and the spleen deficiency causing phlegm-fluid retention type. Methods:A total of 60 patients were divided into treatment group and control group according to the time sequence of seeing doctor,with30 cases in each group. Patients in the treatment group were treated with oral administration of YQSFWYHYF,while patients in the control group were treated with inhalation of Budesonide formoterol and oral administration of montelukast sodium tablets. One month as one course of treatment,both the two groups were treated for two months. The allergic rhinitis symptom score,asthma symptom score,eosinophil cout,pulmonary function index level of the two groups were compared before and after treatment,and the curative efficacy of the two groups were evaluated. Results:After treatment,the allergic rhinitis symptom score and the asthma symptom score of the two groups were lower than those before treatment(P<0.05),and the scores of the treatment group were lower than those of the control group(P<0.05). The eosinophil cout of the treatment group after treatment was less than that before treatment(P<0.05),and was also less than that of the control group(P<0.05). The levels of pulmonary function indexes of the treatment group such as forced vital capacity(FVC),forced expiratory volume in first second(FEV1),FEV1/FVC,peak expiratory flow(PEF),PEF25%,PEF50%,PEF75% and FEF25%～75% after treatment were higher than those before treatment(P<0.05),while in the control group,only the level of PEF was higher than that before treatment(P <0.05). The total effective rate of the treatment group and the control group was 96.7% and80.0%,respectively. The total effective rate of the treatment group was higher than that of the control group(P<0.05). Conclusion:In treatment of CARAS of the lung and the spleen deficiency causing phlegm-fluid retention type,YQSFWYHYF can relieve the clinical symptoms and improve the pulmonary function and curative efficacy.